Business Wire

REPLY: The Internet of Things, Together With the Evolution of 5G and Edge Computing, Is Driving Industrial Innovation

1.9.2021 11:00:00 EEST | Business Wire | Press release

Share

Reply’s latest research Industrial IoT: A Reality Check ” explores two key areas that are driving the growth of IoT within the industrial market: smart factory and smart transport & logistics. By connecting machinery and tools, the Industrial IoT (IIoT) enables manufacturing companies to improve the visibility of their production in real time. The huge amount of data generated by Industrial IoT devices constitutes the fuel for optimising production, improving the delivery quality, introducing predictive maintenance, automating the supply chain and much more.

“Without the Industrial IoT, Industry 4.0 cannot exist. Data are the fuel for all “smart” use cases in the industrial world; Industrial IoT is the crucial element that guarantees the infrastructure to collect data, to send them to the cloud and to manage the feedback post-analysis, all as part of a virtuous circle of benefits to business”, explains Filippo Rizzante, Reply CTO.

Market growth

The research, carried out thanks to the data collected with the use of the proprietary Trend Sonar platform and the support provided by the Teknowlogy Group, also examines the main markets for smart factories and smart transport & logistics, grouped into two clusters: “Europe-5” (Germany, Italy, France, Belgium and the Netherlands) and “Big-5” (the USA, China, India, Brazil and the UK).

Despite the though economic climate of 2020, both clusters saw a small growth in investments in smart factories, as well as in the smart transport & logistics area, while further and much more significant growth is expected by 2025. Overall, the smart factory market of the “Big-5” cluster, led by the US, is expected to exceed €86 billion by 2025, with strong investments in platforms, predictive solutions and remote monitoring. The smart transport & logistics market is set to exceed €15 billion. In the “Europe-5” cluster, on the other hand, the smart factory market is expected to nearly triple in all countries, reaching a total of over €23 billion in the five countries in question, with Germany in the lead. Platforms are set to experience exponential growth and businesses will invest to manage quality better and to reduce costs. Germany will also remain the leader in the smart transport & logistics area, but the other countries in the cluster will still see significant growth. This Cluster is expected to reach a total value of €3.6 billion in 2025.

The drive of 5G and edge computing

The adoption of low-cost sensors and 5G networks, driven by large investments by Telcos, will further improve the diffusion of Industrial IoT. For example, improved communication between autonomous vehicles/robots, artificial intelligence and machinery, combined with increased computing power and very low latency, is expected to improve not only the efficiency of plants, but also their safety. Moreover, the ability to create high-density private networks will enable a wider deployment of the Industrial IoT, as well as the connection of a significant number of sensors, machinery, vehicles and robots, complemented by a greater use of augmented and virtual reality to support “connected workers”.

Cybersecurity is a crucial factor

The constant growth of connected devices and their heterogeneity requires bold security management of the setup and maintenance policy of both devices and networks. Based on its experience, Reply believes that organisations need to adopt micro-segmented environments (on-premises and/or cloud-based), which are stable and ready to react to both traditional and new dangerous technologies and techniques, thus reducing the probability that new types of attacks will be successful. The analysis of IoT architecture, of industrial components and of entire infrastructures will help companies to eliminate existing gaps, vulnerabilities and threats in advance. But this is much more than merely a technological issue: training programmes aimed at employees, together with the study and continuous testing of all devices used will also be crucial.

From factories to consumers

If, in recent years, Industrial Internet of Things technologies have been adopted and used, above all, to improve the efficiency of factories and logistics centres, during the pandemic, new investments have been directed primarily towards improving worker safety. The long-term trend, however, is expected to directly involve final consumers. The success of so-called “connected products” is, in fact, accelerating investments towards solutions in which the collection and processing of usage data does not only involve production machinery, but also the use of finished products. The redesign of design, production and distribution processes of IoT-connected products is enabling the creation of value-added services and facilitating the ability to remotely update and maintain household appliances, cars, robots, electronics and entertainment devices.

For more information on the “Industrial IoT: A Reality Check” research. This new research is part of the Reply Market Research series, which includes the “From Cloud to Edge”, “New Interfaces, Zero Interfaces” and “Beyond Digital Marketing” papers.

Reply

Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on the new communication channels and digital media. Through its network of highly specialised companies, Reply partners with major European corporations in the telecoms and media, industry and services, banking and insurance and public administration sectors, to devise and develop business models built on the new paradigms of artificial intelligence, big data, cloud computing, digital media and the Internet of Things. Reply’s services include: Consulting, Systems Integration and Digital Services. www.reply.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contacts
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594

Aaron Miani
a.miani@reply.com
Tel. +44 (0)20 7730 6000

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye